• linkedin
  • Increase Font
  • Sharebar

    Prostate Ca: Immunotherapy consensus statement published

    The authors of the first evidence-based consensus statement on the use of immunotherapy to treat prostate cancer recommend using immunotherapy first, followed by an androgen receptor-targeted agent, for metastatic castration-resistant disease.

    Related - PCa immunotherapy: Response better when given before ADT

    The Society for Immunotherapy of Cancer published the consensus statement in the open-access Journal for ImmunoTherapy of Cancer (2016; 4:92).

    “The new prostate cancer treatment guidelines, from a panel convened by the Society for Immunotherapy of Cancer (SITC), come at a time when immunotherapy is showing such promise across a wide range of cancers,” James L. Gulley, MD, PhD, of the National Institutes of Health, Center for Cancer Research and chair of the SITC Prostate Cancer Task Force, told Urology Times. “These guidelines are part of a programmatic effort to put forth our current understanding of the best practices vis-à-vis immunotherapy in multiple cancer types. Of interest, there are other guidelines that are just out from SITC [regarding] hematologic malignancies and renal cell cancer.”

    The society’s statement on prostate cancer represents a consensus from a broad group, including medical oncology, radiation oncology, urology, nursing, and patient advocacy, with several being key opinion leaders in prostate cancer immunotherapy, according to Dr. Gulley.

    Also see - RCC: Multiple pathways provide therapeutic targets

    “There is one FDA-approved immunotherapy in prostate cancer, sipuleucel-T [Provenge], and this is indicated for asymptomatic or minimally symptomatic metastatic castration-resistant prostate cancer,” he said. “[The indication] was based on a statistically significant and clinically meaningful improvement in overall survival (level 1 evidence).”

    Next: "The general consensus was that there are major characteristics of mCRPC that favor an immunotherapy approach."

    Lisette Hilton
    Lisette Hilton, president of Words Come Alive, has written about health care, the science and business of medicine, fitness and wellness ...


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available